Nuveen Asset Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q4 | $7.24M | Sell |
355,057
-360,243
| -50% | -$7.34M | ﹤0.01% | 1785 |
|
2024
Q3 | $20.8M | Sell |
715,300
-358,557
| -33% | -$10.4M | 0.01% | 1165 |
|
2024
Q2 | $24.9M | Buy |
1,073,857
+565,661
| +111% | +$13.1M | 0.01% | 987 |
|
2024
Q1 | $10.4M | Buy |
508,196
+188,759
| +59% | +$3.87M | ﹤0.01% | 1561 |
|
2023
Q4 | $6.86M | Sell |
319,437
-44,228
| -12% | -$949K | ﹤0.01% | 1798 |
|
2023
Q3 | $7.5M | Sell |
363,665
-1,791
| -0.5% | -$36.9K | ﹤0.01% | 1644 |
|
2023
Q2 | $10.8M | Buy |
365,456
+4,820
| +1% | +$142K | ﹤0.01% | 1470 |
|
2023
Q1 | $8.31M | Sell |
360,636
-15,111
| -4% | -$348K | ﹤0.01% | 1602 |
|
2022
Q4 | $10.4M | Buy |
375,747
+24,288
| +7% | +$675K | ﹤0.01% | 1460 |
|
2022
Q3 | $10.8M | Sell |
351,459
-8,699
| -2% | -$267K | ﹤0.01% | 1428 |
|
2022
Q2 | $10.6M | Sell |
360,158
-10,071
| -3% | -$296K | ﹤0.01% | 1467 |
|
2022
Q1 | $12.3M | Sell |
370,229
-6,815
| -2% | -$227K | ﹤0.01% | 1514 |
|
2021
Q4 | $16.8M | Buy |
377,044
+11,966
| +3% | +$534K | 0.01% | 1333 |
|
2021
Q3 | $19.3M | Sell |
365,078
-18,982
| -5% | -$1M | 0.01% | 1297 |
|
2021
Q2 | $30.1M | Buy |
384,060
+106,439
| +38% | +$8.35M | 0.01% | 1069 |
|
2021
Q1 | $15.9M | Sell |
277,621
-14,241
| -5% | -$813K | 0.01% | 1490 |
|
2020
Q4 | $24.4M | Sell |
291,862
-36,489
| -11% | -$3.06M | 0.01% | 1121 |
|
2020
Q3 | $11.8M | Sell |
328,351
-1,328
| -0.4% | -$47.6K | ﹤0.01% | 1416 |
|
2020
Q2 | $7.97M | Buy |
329,679
+46,241
| +16% | +$1.12M | ﹤0.01% | 1641 |
|
2020
Q1 | $4.96M | Buy |
283,438
+103,045
| +57% | +$1.8M | ﹤0.01% | 1720 |
|
2019
Q4 | $3.14M | Buy |
180,393
+1,163
| +0.6% | +$20.3K | ﹤0.01% | 2233 |
|
2019
Q3 | $2.75M | Buy |
179,230
+4,255
| +2% | +$65.2K | ﹤0.01% | 2256 |
|
2019
Q2 | $3.63M | Buy |
+174,975
| New | +$3.63M | ﹤0.01% | 2155 |
|